Abstract 3988
Background
PD-1 blockade on Regulatory T cells (Tregs) increases resistance of effector T cells to Tregs suppression and directly reduces in vitro Tregs suppressive function. NKs expressed PD-1 and engagement of PD-1 reduces their cytolysis potential. and the effect of CXCR4 antagonism are evaluated on ex vivo Tregs and NKs.
Methods
43 Nivolumab treated-mRCC patients, 20 other than ICI treated –mRCC (CTR) and 15 Healthy donors (HD) were enrolled. 29 patients underwent first clinical evaluation at 3 months resulting in 23 patients with Objective Response (OR) and 6 in progression (PD). Tregs (CD4+CD25+CD127lowFOXP3+) and NKs (CD3-CD56+CD107a+) phenotype and function were evaluated at day 0, 14, 28, 90, and 180. CFSE-T-effector proliferation-Treg dependent and CD107a externalization toward K562 as NK function were evaluated.
Results
29 patients underwent first clinical evaluation at 3 months resulting in 23 patients with Objective Response (OR) and 6 in progression (PD). Higher NKG2D was reported on CD3-CD56dim cells from OR patients as compared to PD patients (p = 0.0054). A clear reduction in NK basal activity was detected at T0 in 3 months progressed Nivolumab treated patients (p = 0.029). Percent of basal Tregs CD4+CD25+CD127lowFOXP3+ was robustly high (p < 0.001) and CD8/Tregs ratio low (p < 0.001) in 63 mRCC patients as compared to 15 HD. Significant lower PD-1 in Treg cells was observed at 3 months treatment in OR patients ( p = 0.048) and a decrease of HELIOS was showed in PD vs OR patients at time 0 (p = 0.017). Ex vivo Tregs were significantly inhibited by CXCR4 antagonism at day 14 in OR patients (p = 0.0024). Characterization of primary RCCs tumor microenvironment and proteomic/ cyto-chemokines profile are ongoing.
Conclusions
Basal NK activity and early detection (2 weeks) of CXCR4 dependent reversal of Treg suppressive activity significantly discriminates mRCC Nivolumab responding patients.
Clinical trial identification
NCT03891485.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Transcan 2016.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract